News and Trends 20 Dec 2014
French Biotech Start-up Adocia signs Massive €464M Diabetes Deal with Eli Lilly
The French biotechnology company Adocia entered into an alliance with the US Eli Lilly on the co-development of an ultra-fast insulin to treat type 1 and type 2 diabetes. This insuline, called BioChaperone Lispro, has been developed through Adocia’s technology BioChaperone, is currently in Phase Ib clinical study. Under this global license agreement with Adocia, Eli Lilly […]